JNJ’s Rally Reflects Growth Beyond Its Stelara Decline
Johnson & Johnson shares climbed despite slower revenue growth, as investors weigh new-drug momentum against Stelara losses and softer MedTech sales.
Makkler Newsroom · Sep 24, 11:25 AM · 1 min read
